Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Allergy and Clinical Immunology: In Practice

• Publication date

  2017-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jaip.2017.10.020PMID 29133221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

  2017cited by this paper
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): An Interplay among Drugs, Viruses, and Immune System

  2017cited by this paper
• Drug reaction with eosinophilia and systemic symptoms (DRESS): incidence, pathogenesis and management

  2016cited by this paper
• Adverse cutaneous drug eruptions: current understanding

  2015cited by this paper
• Drug reaction with eosinophilia and systemic symptoms syndrome.

  2015cited by this paper
• DRESS syndrome: Part II. Management and therapeutics.

  2013cited by this paper
• Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug‐induced hypersensitivity syndrome

  1998cited by this paper

• DRESS als seltene Differentialdiagnose bei Eosinophilie, Hautexanthem und akuter Hepatitis

  2024cites this paper
• Demystifying drug reaction with eosinophilia and systemic symptoms (DRESS): a review of the literature and guidelines for management

  2024cites this paper
• Terapia direcionada para doenças imunomediadas da pele. O que o dermatologista deve saber?

  2024cites this paper
• Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

  2024cites this paper
• Severe cutaneous adverse reactions

  2024cites this paper
• Helper T cell subsets: Development, function and clinical role in hypersensitivity reactions in the modern perspective

  2024cites this paper
• Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part II. Diagnosis and Management.

  2023cites this paper
• Cutaneous adverse drug reactions.

  2023cites this paper
• Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome

  2023cites this paper
• Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review

  2023cites this paper
• Renal Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review of 71 Cases

  2023cites this paper
• Le DRESS syndrome en 2023

  2023cites this paper
• Targeting interleukin‐5 with benralizumab: A novel treatment for drug rash with eosinophilia and systemic symptoms

  2022cites this paper
• Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study

  2022cites this paper
• Current and emerging biologic therapies targeting eosinophilic disorders

  2022cites this paper
• Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)

  2022cites this paper
• Case 32-2022: A 76-Year-Old Man with Postoperative Cardiogenic Shock and Diffuse Rash.

  2022cites this paper
• Controversies in Allergy: The potential role of biologics as first line therapy in eosinophilic disorders.

  2022cites this paper
• Drug Reaction with Eosinophilia and Systemic Symptoms: A Complex Interplay between Drug, T Cells, and Herpesviridae

  2021cites this paper
• Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis

  2021cites this paper
• Current Perspectives on Severe Drug Eruption

  2021cites this paper
• Successful Treatment of Imatinib-Induced DRESS Syndrome Using Reslizumab without Cessation of Imatinib: A Case Report

  2021cites this paper
• When fever is more than infection: two cases of vancomycin-induced drug reaction with eosinophilia and systemic symptoms (DRESS)

  2021cites this paper
• Eosinophils in skin diseases

  2021cites this paper
• Delayed hypersensitivity to antiepileptic drugs in children

  2020cites this paper
• SYMPTOMATIC TREATMENT AVAILABLE TREATMENT OPTIONS UPDATE AND REVIEW OF LITERATURE Classification of literature on evidence level regarding treatment with corticosteroids

  2020cites this paper
• Benralizumab for severe DRESS in two COVID-19 patients

  2020cites this paper
• Mepolizumab rescue therapy for acute pneumonitis secondary to DRESS

  2019cites this paper
• The Journal of Allergy and Clinical Immunology: In Practice 2018 Highlights.

  2019cites this paper
• Drug reaction with eosinophilia and systemic symptoms (DRESS) in children.

  2019cites this paper
• Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances

  2019cites this paper
• Critical Points on the Use of Biologicals in Allergic Diseases and Asthma

  2019cites this paper
• Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma

  2018cites this paper
• High-risk drug rashes.

  2018cites this paper
• Cefepime/cotrimoxazole

  2018cites this paper
• Anais Brasileiros de Dermatologia

  2004cites this paper